ESR1 and neoplasm: In the clinical context, estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-negative) support breast cancer (BC) treatment decisions, which are guided by the tumor’s genomic signature, such as Oncotype DX Recurrence Score (RS).